Frequency of TERT Promoter Mutations in Prostate Cancer

Pathobiology

Volumn 82, Issue 2, 2015, Pages 53-57

  Stoehr, Robert ^a   Taubert, Helge ^a   Zinnall, Ulrike ^a   Giedl, Johannes ^a   Gaisa, Nadine T ^b   Burger, Maximilian ^c   Ruemmele, Petra ^d   Hurst, Carolyn D ^e   Knowles, Margaret A ^e   Wullich, Bernd ^a   Hartmann, Arndt ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Caritas St Josef Medical Centre   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Mutation; Promoter; Prostate cancer; Sanger sequencing; SNaPshot analysis; TERT

Indexed keywords

FORMALDEHYDE; PARAFFIN; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CARCINOGENESIS; CRYOPRESERVATION; DNA ISOLATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; WILD TYPE; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENETICS; MUTATION; PROSTATIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; HUMANS; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TELOMERASE;

EID: 84929692783     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000381903     Document Type: Article

References (27)

1. Babaei S, Hulsman M, Reinders M, de Ridder J: Detecting recurrent gene mutation in interaction network context using multi-scale graph diffusion. BMC Bioinformatics 2013; 14: 29.
2. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-961.
3. Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, Maximo V, Sobrinho-Simoes M, Soares P: Telomerase promoter mutations in cancer: An emerging molecular biomarker? Virchows Arch 2014; 465: 119-133.
4. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957-959.
5. Meeker AK: Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol 2006; 24: 122-130.
6. Kamradt J, Drosse C, Kalkbrenner S, Rohde V, Lensch R, Lehmann J, Fixemer T, Bonkhoff H, Stoeckle M, Wullich B: Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: A real-time quantification and in situ hybridization study. Lab Invest 2003; 83: 623-633.
7. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA: D D3P CA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-2698.
8. Korkmaz M, Avci CB, Gunduz C, Aygunes D, Erbaykent-Tepedelen B: Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells. Tumour Biol 2014; 35: 1531-1538.
9. Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Ip C, Cheng H, Rennie PS, Horikawa I, Lustig AJ, Yu Q, Zhang H, Dong Y: Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Mol Cancer Ther 2010; 9: 2016-2025.
10. Guo C, Armbruster BN, Price DT, Counter CM: In vivo regulation of hTERT expression and telomerase activity by androgen. J Urol 2003; 170: 615-618.
11. Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A: Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: A novel role of AR mutation for prostate cancer development. FASEB J 2008; 22: 1258-1267.
12. Williams JL, Greer PA, Squire JA: Recurrent copy number alterations in prostate cancer: An in silico meta-analysis of publicly available genomic data. Cancer Genet 2014; 207: 478-488.
13. Killela PJ, Reitman ZJ, Jiao Y, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013; 110: 6021-6026.
14. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, Chen C, Lv Z, Tang A, Sun X, Lu J, Li W, Zhou J, Gui Y, Zhou F, Wang D, Cai Z: Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: A genomic and molecular study. Eur Urol 2014; 65: 274-277.
15. Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT 3rd, Yang XJ, Argani P, Netto GJ, Zhong M: High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 2014; 7: 47.
16. Epstein JI AF, Allsbrook WC, et al: Tumours of the prostate; in Eble JN Sauter G, Epstein JI, Sesterhenn IA: (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, ed 1. Lyon, IARC, 2004.
17. Sobin LH WC: TNM Classification of Malignant Tumors, ed 6. New York, John Wiley and Sons, 2002.
18. Hurst CD, Platt FM, Knowles MA: Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2014; 65: 367-369.
19. Baca SC, Prandi D, Lawrence MS, et al: Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-677.
20. Kote-Jarai Z, Saunders EJ, Leongamornlert DA, et al: Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013; 22: 2520-2528.
21. Kote-Jarai Z, Olama AA, Giles GG, et al: Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-791.
22. Yoon SL, Jung SI, Do EJ, Lee SR, Lee SY, Chu IS, Kim WJ, Jung J, Kim CS, Cheon SH, Leem SH: Short rare hTERT-VNTR2-2 nd alleles are associated with prostate cancer susceptibility and influence gene expression. BMC Cancer 2010; 10: 393.
23. Leem SH, Londono-Vallejo JA, Kim JH, Bui H, Tubacher E, Solomon G, Park JE, Horikawa I, Kouprina N, Barrett JC, Larionov V: The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions. Oncogene 2002; 21: 769-777.
24. Matsumura Y, Shimada K, Tanaka N, Fujimoto K, Hirao Y, Konishi N: Phosphorylation status of Fas-associated death domaincontaining protein regulates telomerase activity and strongly correlates with prostate cancer outcomes. Pathobiology 2009; 76: 293-302.
25. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N: Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005; 206: 423-432.
26. Daniel M, Peek GW, Tollefsbol TO: Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012; 498: 135-146.
27. Hrdlickova R, Nehyba J, Bargmann W, Bose HR Jr: Multiple tumor suppressor microRNAs regulate telomerase and TCF7, an important transcriptional regulator of the Wnt pathway. PloS One 2014; 9:e86990.